HRP20201651T1 - Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola - Google Patents
Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola Download PDFInfo
- Publication number
- HRP20201651T1 HRP20201651T1 HRP20201651TT HRP20201651T HRP20201651T1 HR P20201651 T1 HRP20201651 T1 HR P20201651T1 HR P20201651T T HRP20201651T T HR P20201651TT HR P20201651 T HRP20201651 T HR P20201651T HR P20201651 T1 HRP20201651 T1 HR P20201651T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- use according
- ldl
- subject
- human
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562158157P | 2015-05-07 | 2015-05-07 | |
| EP16790128.9A EP3292144B1 (en) | 2015-05-07 | 2016-05-06 | Use of cd24 for lowering low-density lipoprotein cholesterol levels |
| PCT/US2016/031109 WO2016179456A1 (en) | 2015-05-07 | 2016-05-06 | Use of cd24 for lowering low-density lipoprotein cholesterol levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201651T1 true HRP20201651T1 (hr) | 2020-12-25 |
Family
ID=57218627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201651TT HRP20201651T1 (hr) | 2015-05-07 | 2016-05-06 | Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10369197B2 (https=) |
| EP (1) | EP3292144B1 (https=) |
| JP (1) | JP6751756B2 (https=) |
| KR (1) | KR20170141216A (https=) |
| CN (1) | CN107531772B (https=) |
| AU (1) | AU2016258084B2 (https=) |
| BR (1) | BR112017022394A2 (https=) |
| CA (1) | CA2982612A1 (https=) |
| EA (1) | EA038520B1 (https=) |
| ES (1) | ES2829235T3 (https=) |
| HK (1) | HK1249521A1 (https=) |
| HR (1) | HRP20201651T1 (https=) |
| HU (1) | HUE051866T2 (https=) |
| IL (1) | IL255086B (https=) |
| MX (1) | MX385941B (https=) |
| PT (1) | PT3292144T (https=) |
| WO (1) | WO2016179456A1 (https=) |
| ZA (1) | ZA201706846B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017022394A2 (pt) * | 2015-05-07 | 2018-07-17 | Oncoimmune Inc | uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade |
| WO2018165204A1 (en) * | 2017-03-07 | 2018-09-13 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating systemic lupus erythematosus |
| WO2019113123A1 (en) * | 2017-12-04 | 2019-06-13 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| JP2021523929A (ja) * | 2018-03-05 | 2021-09-09 | オンコイミューン， インコーポレイテッド | 後天性免疫不全症候群（ｈｉｖ／ａｉｄｓ）の治療のための可溶性ｃｄ２４の使用方法 |
| WO2019236474A1 (en) * | 2018-06-04 | 2019-12-12 | Oncoimmune, Inc. | Methods of use of cd24 for the prevention and treatment of leukemia relapse |
| EP3870604B1 (en) | 2018-10-26 | 2022-11-23 | F. Hoffmann-La Roche AG | Multispecific antibody screening method using recombinase mediated cassette exchange |
| EP3921338A4 (en) * | 2019-02-06 | 2022-11-23 | Oncoimmune Inc. | TARGETED CD24-SIGLEC INTERACTIONS TO TREAT AND PREVENT NON-ALCOHOLIC STEATOHEPATITIS |
| US20220000974A1 (en) * | 2019-02-06 | 2022-01-06 | Oncolmmune, Inc. | Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes |
| WO2021160173A1 (en) * | 2020-02-10 | 2021-08-19 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating viral pneumonia |
| WO2021160170A1 (en) * | 2020-02-10 | 2021-08-19 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating sars-cov-2 infection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544566B1 (en) * | 1999-04-23 | 2003-04-08 | Protein Technologies International, Inc. | Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol |
| EP1267909B1 (en) * | 2000-03-29 | 2010-07-28 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive t cells |
| CN1323544A (zh) * | 2000-05-13 | 2001-11-28 | 蛋白质技术国际公司 | 降低低密度脂蛋白胆固醇浓度的组合物和方法 |
| US20110002846A1 (en) * | 2007-12-21 | 2011-01-06 | Univeristy of Rochester | Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain |
| US8163281B2 (en) * | 2009-03-04 | 2012-04-24 | The Regents Of The University Of Michigan | Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis |
| US8354520B2 (en) * | 2009-12-10 | 2013-01-15 | Kaohsiung Medical University | Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug |
| DK2563385T3 (da) * | 2010-04-28 | 2017-11-06 | Oncoimmune Inc | Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis |
| US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
| AU2012267489B2 (en) * | 2011-06-10 | 2017-03-16 | The Trustees Of The University Of Pennsylvania | System and method of cytomic vascular health profiling |
| BR112017022394A2 (pt) * | 2015-05-07 | 2018-07-17 | Oncoimmune Inc | uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade |
-
2016
- 2016-05-06 BR BR112017022394A patent/BR112017022394A2/pt not_active IP Right Cessation
- 2016-05-06 JP JP2018510322A patent/JP6751756B2/ja not_active Expired - Fee Related
- 2016-05-06 WO PCT/US2016/031109 patent/WO2016179456A1/en not_active Ceased
- 2016-05-06 EP EP16790128.9A patent/EP3292144B1/en active Active
- 2016-05-06 ES ES16790128T patent/ES2829235T3/es active Active
- 2016-05-06 HK HK18107984.3A patent/HK1249521A1/zh unknown
- 2016-05-06 PT PT167901289T patent/PT3292144T/pt unknown
- 2016-05-06 CN CN201680026449.2A patent/CN107531772B/zh not_active Expired - Fee Related
- 2016-05-06 US US15/572,330 patent/US10369197B2/en not_active Expired - Fee Related
- 2016-05-06 CA CA2982612A patent/CA2982612A1/en not_active Abandoned
- 2016-05-06 EA EA201792418A patent/EA038520B1/ru unknown
- 2016-05-06 MX MX2017014095A patent/MX385941B/es unknown
- 2016-05-06 HR HRP20201651TT patent/HRP20201651T1/hr unknown
- 2016-05-06 KR KR1020177032235A patent/KR20170141216A/ko not_active Ceased
- 2016-05-06 HU HUE16790128A patent/HUE051866T2/hu unknown
- 2016-05-06 AU AU2016258084A patent/AU2016258084B2/en not_active Ceased
-
2017
- 2017-10-10 ZA ZA2017/06846A patent/ZA201706846B/en unknown
- 2017-10-17 IL IL255086A patent/IL255086B/en unknown
-
2019
- 2019-06-17 US US16/443,498 patent/US11026995B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2982612A1 (en) | 2016-11-10 |
| EA201792418A1 (ru) | 2018-02-28 |
| AU2016258084B2 (en) | 2020-01-30 |
| ES2829235T3 (es) | 2021-05-31 |
| WO2016179456A1 (en) | 2016-11-10 |
| US11026995B2 (en) | 2021-06-08 |
| US10369197B2 (en) | 2019-08-06 |
| EP3292144A4 (en) | 2018-11-14 |
| US20190307841A1 (en) | 2019-10-10 |
| EP3292144B1 (en) | 2020-08-26 |
| MX385941B (es) | 2025-03-18 |
| AU2016258084A1 (en) | 2017-11-02 |
| JP2018515605A (ja) | 2018-06-14 |
| EP3292144A1 (en) | 2018-03-14 |
| PT3292144T (pt) | 2020-11-05 |
| IL255086A0 (en) | 2017-12-31 |
| HUE051866T2 (hu) | 2021-03-29 |
| CN107531772B (zh) | 2021-09-21 |
| BR112017022394A2 (pt) | 2018-07-17 |
| ZA201706846B (en) | 2018-12-19 |
| HK1249521A1 (zh) | 2018-11-02 |
| KR20170141216A (ko) | 2017-12-22 |
| MX2017014095A (es) | 2018-03-16 |
| IL255086B (en) | 2021-08-31 |
| JP6751756B2 (ja) | 2020-09-09 |
| EA038520B1 (ru) | 2021-09-09 |
| CN107531772A (zh) | 2018-01-02 |
| US20180110828A1 (en) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201651T1 (hr) | Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola | |
| MX2024004322A (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| MX386942B (es) | Anticuerpos que comprenden regiones constantes pesadas modificadas. | |
| ES2422479T3 (es) | Combinación de inhibición de BLyS y micofenolato de mofetilo para tratamiento de enfermedades autoinmunitarias | |
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| EA201291181A1 (ru) | Композиции и способы применения терапевтических поливалентных антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
| ATE513563T1 (de) | Therapeutische und toleranz-induzierende antikörper | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| MX391804B (es) | Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. | |
| HRP20191109T1 (hr) | Gdf klopke za uporabu u liječenju anemije | |
| EP4434543A3 (en) | Human igg1 fc region variants and uses thereof | |
| PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
| DK1624892T3 (da) | Terapeutisk anvendelse af anti-CSI-antistoffer | |
| HRP20251426T1 (hr) | Sastavi i postupci za modulaciju faktora rasta | |
| RU2011109178A (ru) | Антагонисты pcsk9 | |
| EP4527403A3 (en) | Dual function proteins and pharmaceutical composition comprising same | |
| EA200970262A1 (ru) | Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| SI2004688T2 (sl) | Izboljšana protofibrilno selektivna protitelesa in njihova uporaba | |
| AR074427A1 (es) | Composiciones estables de anticuerpos y metodos para estabilizarlas | |
| FI3569620T3 (fi) | Ihmisen cgrp-reseptoria sitovat vasta-aineet | |
| BR112013008407A2 (pt) | antígenos de clostridium difficile | |
| WO2011002968A3 (en) | Polypeptides and method of treatment | |
| UA130540C2 (uk) | Композиція антитіла b7-h4 | |
| ATE314062T1 (de) | Zusammensetzungen zur abgabe von cortisolantagonisten |